ASCO 2025: The Seismic Shift for CDMOs – Adapt or Become the Bottleneck
The flood of clinical data and therapeutic breakthroughs from the ASCO 2025 Annual Meeting has subsided. But for leaders in the Contract Development and Manufacturing Organization (CDMO) space, the most critical takeaways weren’t just about the new drugs. The real story, lurking behind the headlines on AI and antibody-drug conjugates (ADCs), is a fundamental […]